Life
FDA and NIH Initiate New Strategies to Minimize Animal Testing in Drug Development
The Department of Health and Human Services (HHS) has prioritized the reduction of animal testing in drug development, reflecting a shift towards alternative methodologies.
Editorial Staff
1 min read
The FDA and NIH have announced new initiatives aimed at decreasing reliance on animal testing within the drug development process. This aligns with the HHS's ongoing commitment to reduce animal use in research.
These initiatives may involve the adoption of advanced in vitro methods and computational models, which could enhance the efficiency and ethical standards of drug testing.
The move is part of a broader trend in regulatory science, seeking to improve the throughput of drug development while addressing ethical concerns associated with animal testing.